Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alix Portal
Reply to the Comment on ‘Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Adenocarcinoma After Folfirinox Failure: An AGEO Prospective Multicentre Cohort’
British Journal of Cancer
Cancer Research
Oncology
Related publications
Neoadjuvant Treatment With Gemcitabine Plus Nab-Paclitaxel Versus Surgery First for Pancreatic Adenocarcinoma
HPB
Hepatology
Gastroenterology
Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer
Cancer Management and Research
Oncology
Comparative Effectiveness of Nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
Advances in Therapy
Medicine
Pharmacology
A Granulocyte Colony-Stimulating Factor-Producing Pancreatic Adenocarcinoma Treated With Nab-Paclitaxel Plus Gemcitabine Chemotherapy
Suizo
Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With Nab-Paclitaxel and Gemcitabine
Pancreas
Internal Medicine
Endocrinology
Hepatology
Metabolism
Diabetes
NeoadjuvantNab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
Anticancer Research
Medicine
Cancer Research
Oncology
Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial
BMC Cancer
Cancer Research
Oncology
Genetics
Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study
British Journal of Cancer
Cancer Research
Oncology
